CNS Pharmaceuticals Q2 2024 Net Loss Reduced To $2.5M Due To Lower CRO Expenses; R&D Costs Decrease To $1.1M; G&A Expenses Increase To $1.4M Due To Higher Legal And Professional Fees

Benzinga08-15

Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data Expected H1 2025

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459426188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-15 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459426188","market":"us","top_or_hot":-1,"title":"CNS Pharmaceuticals Q2 2024 Net Loss Reduced To $2.5M Due To Lower CRO Expenses; R&D Costs Decrease To $1.1M; G&A Expenses Increase To $1.4M Due To Higher Legal And Professional Fees","media":"Benzinga","content":"<html><body><p>Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data Expected H1 2025</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CNS Pharmaceuticals Q2 2024 Net Loss Reduced To $2.5M Due To Lower CRO Expenses; R&D Costs Decrease To $1.1M; G&A Expenses Increase To $1.4M Due To Higher Legal And Professional Fees</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCNS Pharmaceuticals Q2 2024 Net Loss Reduced To $2.5M Due To Lower CRO Expenses; R&D Costs Decrease To $1.1M; G&A Expenses Increase To $1.4M Due To Higher Legal And Professional Fees\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-15 20:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/earnings/24/08/40392907/cns-pharmaceuticals-q2-2024-net-loss-reduced-to-2-5m-due-to-lower-cro-expenses-r-d-costs-decrease-t><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data Expected H1 2025</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/24/08/40392907/cns-pharmaceuticals-q2-2024-net-loss-reduced-to-2-5m-due-to-lower-cro-expenses-r-d-costs-decrease-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNSP","symbol_name":"CNS Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/24/08/40392907/cns-pharmaceuticals-q2-2024-net-loss-reduced-to-2-5m-due-to-lower-cro-expenses-r-d-costs-decrease-t","article_id":"2459426188","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459426188","pubTimestamp":1723724325,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data Expected H1 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNSP":"CNS Pharmaceuticals, Inc.","BK4007":"制药","BK4135":"资产管理与托管银行","CNS":"科恩-斯蒂尔斯金融"},"translate_title":"由于CRO费用降低，CNS Pharmaceuticals 2024年第二季度净亏损减少至250万美元；研发成本降至110万美元；由于法律和专业费用增加，G&A费用增加至140万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNS":1,"CNSP":0.9},"content_text":"Cash Position At $1.5M With Additional $12.4M Raised Post-June 30; Sufficient Funds Through Q1 2025, Final Berubicin Trial Data Expected H1 2025","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459426188"}